Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

International Stem Cell (ISCO) Preferred Stock Liabilities (2019 - 2025)

International Stem Cell (ISCO) has disclosed Preferred Stock Liabilities for 10 consecutive years, with $4.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Preferred Stock Liabilities changed 0.0% to $4.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $4.3 million, a 0.0% change, with the full-year FY2024 number at $4.3 million, changed 0.0% from a year prior.
  • Preferred Stock Liabilities was $4.3 million for Q3 2025 at International Stem Cell, roughly flat from $4.3 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $4.3 million in Q1 2021 to a low of $4.3 million in Q1 2021.
  • A 5-year average of $4.3 million and a median of $4.3 million in 2021 define the central range for Preferred Stock Liabilities.
  • Biggest YoY gain for Preferred Stock Liabilities was 0.0% in 2021; the steepest drop was 0.0% in 2021.
  • International Stem Cell's Preferred Stock Liabilities stood at $4.3 million in 2021, then changed by 0.0% to $4.3 million in 2022, then changed by 0.0% to $4.3 million in 2023, then changed by 0.0% to $4.3 million in 2024, then changed by 0.0% to $4.3 million in 2025.
  • Per Business Quant, the three most recent readings for ISCO's Preferred Stock Liabilities are $4.3 million (Q3 2025), $4.3 million (Q2 2025), and $4.3 million (Q1 2025).